334 related articles for article (PubMed ID: 34771008)
1. A Comprehensive Analysis of the Efficacy of Resveratrol in Atherosclerotic Cardiovascular Disease, Myocardial Infarction and Heart Failure.
Raj P; Thandapilly SJ; Wigle J; Zieroth S; Netticadan T
Molecules; 2021 Oct; 26(21):. PubMed ID: 34771008
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review.
Dyck GJB; Raj P; Zieroth S; Dyck JRB; Ezekowitz JA
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791450
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol improves cardiac function and exercise performance in MI-induced heart failure through the inhibition of cardiotoxic HETE metabolites.
Matsumura N; Takahara S; Maayah ZH; Parajuli N; Byrne NJ; Shoieb SM; Soltys CM; Beker DL; Masson G; El-Kadi AOS; Dyck JRB
J Mol Cell Cardiol; 2018 Dec; 125():162-173. PubMed ID: 30381233
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 blockade in cardiovascular diseases: a clinical update.
Buckley LF; Abbate A
Eur Heart J; 2018 Jun; 39(22):2063-2069. PubMed ID: 29584915
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol and Cardiac Fibrosis Prevention and Treatment.
Zivarpour P; Reiner Ž; Hallajzadeh J; Mirsafaei L
Curr Pharm Biotechnol; 2022; 23(2):190-200. PubMed ID: 33583368
[TBL] [Abstract][Full Text] [Related]
6. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
Shavadia JS; Zheng Y; Green JB; Armstrong PW; Westerhout CM; McGuire DK; Cornel JH; Holman RR; Peterson ED
Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
[TBL] [Abstract][Full Text] [Related]
7. The Effects of Resveratrol on Telomeres and Post Myocardial Infarction Remodeling.
Gutlapalli SD; Kondapaneni V; Toulassi IA; Poudel S; Zeb M; Choudhari J; Cancarevic I
Cureus; 2020 Nov; 12(11):e11482. PubMed ID: 33329978
[TBL] [Abstract][Full Text] [Related]
8. Creatine and creatine analogues in hypertension and cardiovascular disease.
Horjus DL; Oudman I; van Montfrans GA; Brewster LM
Cochrane Database Syst Rev; 2011 Nov; 2011(11):CD005184. PubMed ID: 22071819
[TBL] [Abstract][Full Text] [Related]
9. Chronic Neuregulin-1β Treatment Mitigates the Progression of Postmyocardial Infarction Heart Failure in the Setting of Type 1 Diabetes Mellitus by Suppressing Myocardial Apoptosis, Fibrosis, and Key Oxidant-Producing Enzymes.
Gupte M; Lal H; Ahmad F; Sawyer DB; Hill MF
J Card Fail; 2017 Dec; 23(12):887-899. PubMed ID: 28870731
[TBL] [Abstract][Full Text] [Related]
10. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases.
Zordoky BN; Robertson IM; Dyck JR
Biochim Biophys Acta; 2015 Jun; 1852(6):1155-77. PubMed ID: 25451966
[TBL] [Abstract][Full Text] [Related]
12. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative.
Coiro S; Girerd N; Rossignol P; Ferreira JP; Maggioni A; Pitt B; Tritto I; Ambrosio G; Dickstein K; Zannad F
Eur J Heart Fail; 2017 Feb; 19(2):271-279. PubMed ID: 27774703
[TBL] [Abstract][Full Text] [Related]
13. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics.
Jering KS; Claggett B; Pfeffer MA; Granger C; Køber L; Lewis EF; Maggioni AP; Mann D; McMurray JJV; Rouleau JL; Solomon SD; Steg PG; van der Meer P; Wernsing M; Carter K; Guo W; Zhou Y; Lefkowitz M; Gong J; Wang Y; Merkely B; Macin SM; Shah U; Nicolau JC; Braunwald E
Eur J Heart Fail; 2021 Jun; 23(6):1040-1048. PubMed ID: 33847047
[TBL] [Abstract][Full Text] [Related]
14. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
15. The role of anti-inflammatory drugs and nanoparticle-based drug delivery models in the management of ischemia-induced heart failure.
Haley KE; Almas T; Shoar S; Shaikh S; Azhar M; Cheema FH; Hameed A
Biomed Pharmacother; 2021 Oct; 142():112014. PubMed ID: 34391184
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
[TBL] [Abstract][Full Text] [Related]
17. [Multifactorial treatment of atherosclerosis].
Mangas Rojas A; Gómez Rodríguez F
Med Clin (Barc); 2007 Dec; 129(20):785-96. PubMed ID: 18093481
[TBL] [Abstract][Full Text] [Related]
18. Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence.
De Luca L
Cardiovasc Drugs Ther; 2020 Oct; 34(5):723-735. PubMed ID: 32564304
[TBL] [Abstract][Full Text] [Related]
19. The Cardiovascular Nutrapharmacology of Resveratrol: Pharmacokinetics, Molecular Mechanisms and Therapeutic Potential.
Kroon PA; Iyer A; Chunduri P; Chan V; Brown L
Curr Med Chem; 2010; 17(23):2442-55. PubMed ID: 20491649
[TBL] [Abstract][Full Text] [Related]
20. Atherosclerotic Burden and Heart Failure After Myocardial Infarction.
Gerber Y; Weston SA; Enriquez-Sarano M; Manemann SM; Chamberlain AM; Jiang R; Roger VL
JAMA Cardiol; 2016 May; 1(2):156-62. PubMed ID: 27437886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
